Recombinant Technologies offering is now closed and is no longer accepting investments.


Revolutionary Alzheimer's Treatment

Recombinant Technologies is developing a revolutionary treatment for Alzheimer's Disease. By designing an injection of a molecule treatment to reduce the plaque buildup that causes dementia, we have successfully improved memory in mice and are ready to move toward human trials.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$97,415.25 Raised


Reasons Icon

There are an estimated 5,500,000 people in the U.S. who have Alzheimer’s disease, and we have developed an innovative treatment that addresses the cause of the disease rather than the symptoms. By this treatment strategy, we are addressing a significant unmet medical need and opportunity.

Reasons Icon

Our patented technology was developed over a decade with the support of $4.5 million in grants and has successfully improved memory in mice in our proof of concept trials.

Reasons Icon

Our team is comprised of top experts in their fields, including our founder who trained at Yale School of Medicine for about a decade prior to founding this company.

Treating the Root Cause of Alzheimer’s Disease

We have developed a patented molecule (AmyTrap) with demonstrated success in animal-model proof of concept studies to remove amyloid-beta, which is the physiological cause behind the plaque buildup in the brain associated with Alzheimer's Disease. 

Incorporating that same molecule, we designed and developed two types of extracorporeal devices, called AmyTrappers, for treatments. These proposed innovative devices trap amyloid from circulation (just like dialysis to remove urea in patients with kidney failure) which may lead to achieving a novel treatment strategy that improves the lives of patients with AD.

We are excited about the promising results AmyTrapper has shown up to this point, and are now ready to bring our technology to the next level through new research that will result in the initiation of human trials.

The problem

Current Alzheimer’s Disease Treatments Fall Short

Alzheimer’s Disease (AD) is a common disease leading to dementia affecting millions of people worldwide.  

One of the many targets in treatment for AD is amyloid-beta plaque buildup. However, currently there are no treatments that address amyloid-beta as the underlying pathophysiology behind Alzheimer’s. Instead, most current drugs work to alleviate symptoms or marginally slow disease progression. Recently,  Biogen’s Aduhelm(Adecanumab) was accepted by the FDA  as the first treatment that targets reduction of amyloid- beta plaque in the brain. This underscores the significance of amyloid- beta plaque removal strategies as a key against Alzheimer’s . 

The solution

AmyTrap Treats the Cause, Not Just the Symptoms

Our prototype, AmyTrap, is designed to reduce disease-causing amyloid-beta plaque burden, improving memory by addressing the physiological cause behind Alzheimer’s Disease.

*Image is a computer-generated demo version. Product is still currently under development.

Use of the technology will slow disease progression in individuals at high risk of developing Alzheimer’s disease, increasing the duration of their independence and lessening third-party payor outlay for symptomatic treatments and caregiving.

The market

Meeting a Growing Need in Alzheimer’s Treatment

We estimate the total market size to be approximately $570,000,000 at the growth rate of 17.5% in 2018. 5,500,000 people in the U.S. have Alzheimer’s disease, and 5% of these patients have early-onset Alzheimer’s disease due to genetic or other factors.


The niche therefore consists of 285,000 patients, and at $2000 per year in treatment, that amounts to a $570,000,000 total potential market. We believe that Amytrapper will be one of the few devices in the immediate future to address this unmet medical need by treating this subset population. 

our traction

Promising Early Results and Patented Technology

We have established proof of concept through our animal model, where we saw improved memory and behavior in model mice after treatment. In addition, toxicity and safety assessments in rats and dogs have been completed. Amytrap, the underlying molecule, was found to be safe and non toxic. Further, Amytrapper animal testing is in progress. 

We have achieved Intellectual Property protection in the form of a patent issued by USPTO which has been issued to Recombinant Technologies LLC. We have also won multiple small business innovation grants from the National institutes of Health through a rigorous peer-review process.

what we do

Clearing Plaque Buildup to Improve Memory

AmyTrap is a patented molecule composed of polymer-bound short peptides with the capacity to capture beta-amyloid (Aβ) peptide. Amytrap binds and sequesters Aβ from the circulation, leading to the depletion of amyloid plaques from the brain in model mice. 

Our preliminary studies in animal models suggest that AmyTrap does not enter the brain. Undetectable levels of AmyTrap and reduction of the Aβ burden in the brain suggest that the AmyTrap possibly exerts its therapeutic activity by acting as a peripheral sink for circulatory Aβ. Based on these observations it has been hypothesized that Aβ exists in equilibrium between the brain and in circulation. Sequestration of the circulatory Aβ in the periphery creates an imbalance in this equilibrium driving efflux of Aβ from the brain into the circulation.

The business model

Working with Established Partners to Reach High-Risk Patients

Currently, we are pre-commercialization and looking to perform additional research to perfect our product. 

When we are ready for commercialization, our strategy will initially be aimed at therapy towards individuals at highest risk, in particular those with familial or genetic predisposition for onset of Alzheimer’s disease. We plan to partner with established organizations with a substantial footprint in the marketplace to implement our treatment. 

*Likely to increase overtime

We estimate the cost per treatment to be approximately $500. Four treatments per patient per year are proposed, which would generate revenue of $2000 per patient per year. We are the only player in this market as of now.

How we are different

Our Technology Stops Alzheimer’s at the Source

According to our research, AmyTrapper devices are among the first of their kind in their focus on the depletion of beta amyloid from the brain prior to memory deterioration. Rather than functioning as an anti-beta amyloid antibody, our treatment specifically binds to the critical region of beta amyloid necessary for aggregation.

We expect this breakthrough to significantly improve the living condition of people with Alzheimer’s Disease, especially with its focus on early intervention. 

the vision

Developing a Life-Changing Treatment

We see our technology as an opportunity to improve the lives of the many patients suffering from Alzheimer’s Disease and related dementia. 

Our goal is to complete the studies to get FDA approval of the device within two to three years. Upon this milestone, we plan to exit by outright sale or license the technology out on a milestone and royalty reimbursement model.

our leadership

Experts in Science, Medicine, and Finance

Dr. Pazhani Sundaram, the Founder-President has wide experience in research and development. He was trained at Yale School of Medicine for about a decade prior to founding this company. He has successfully performed a clinical trial on a cholesterol-lowering Indian herbal medicine and commercialized it in the Indian pharmaceutical market.

Our team represents decades of experience across scientific research, biopharmaceuticals, and finance. We believe strongly that this technology will fill an unmet medical need and change many people’s lives for the better. 

why invest

A Unique Treatment for a Better World

In 2021, treatment of patients with Alzhemier’s Disease and dementia will cost the nation $355 billion, and this cost is likely to increase to $1.1 trillion by 2050. We need to change the way we are approaching the problem. 

Through our technological innovation, we believe we can stop beta amyloid plaque build-ups before they happen in the brain, rather than simply treating the symptoms. Our promising proof of concept trial results alongside our patented technology have us well prepared to move into the next phase of trials. 



1090 Meriden Waterbury Tpke, Suite 1
Cheshire, CT 06410


Recombinant Technologies is developing a revolutionary treatment for Alzheimer's Disease. By designing an injection of a molecule treatment to reduce the plaque buildup that causes dementia, we have successfully improved memory in mice and are ready to move toward human trials.


Pazhani Sundaram PhD
Pazhani Sundaram PhD
President, Chief Executive Officer, Interim-CFO, and Chairman of the Board

Dr. Pazhani Sundaram has a Ph.D. in Biochemistry and Molecular Biology. He is the founder of Recombinant Technologies, a pre-clinical stage biotechnology company []. Dr. Sundaram has strong experience in protein expression technologies, molecular biology, biochemistry, peptidomimetics, and in drug delivery systems. Prior to starting Recombinant Technologies in 1998, he was trained at Yale School of Medicine for about a decade. At Yale, Dr. Sundaram contributed to the research and development of a vaccine to treat the human papillomavirus in a rabbit model. This work formed the basis for Merck in developing the vaccine for HPV 16, which was marketed as 'Gardasil'. Dr. Sundaram's research is acknowledged on Merck's patent for the above vaccine.

Dr. Sundaram's focus for the past 19 years has been to develop a viable drug to treat Alzheimer's Disease. He has been awarded multiple SBIR grants and matching grants to perform this task. He is also an inventor of the patented drug called 'Amytrap' to treat Alzheimer's Disease. Current research focuses on the safety/toxicology assessment of this drug with the support of a recent phase 2 SBIR grant award. Efforts are underway to join forces with investors from multiple platforms to expedite the preclinical development activities. Immediate efforts are focused on developing a device called 'Amytrapper' to trap amyloid from circulation utilizing the proprietary API molecule. This research is also supported by a peer-reviewed grant from NIA. 

Amrit Dhawan

Amrit Dhawan


Amrit is responsible for corporate transactions/projects for the efficient administration of the company, particularly with regards to meetings and financial transactions. She has provided support and advice on a managerial and professional level to Yale University for about 19 years. 

Amrit's primary occupation is working for Yale University. She serves as a part-time Secretary for Recombinant Technologies, working 5 hours per week.


Recombinant Technologies
Feb 12, 2022
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares



Recombinant Technologies Inc.

Corporate Address


1090 Meriden Waterbury Tpke, Suite 1, Cheshire, CT 06410

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


Common Stock

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives*


Friends and Family Early Birds

Invest within the first 48 hours and receive additional 20% bonus shares.

Super Early Bird Bonus

Invest within the first week and receive additional 15% bonus shares.

Early Bird Bonus

Invest within the first two weeks and receive an additional 10% bonus shares.


$500+ | Tier 1

Invest $500 and receive 2% bonus shares. 

$1,000+ | Tier 2

Invest $1,000 and receive 5% bonus shares.

$2,500+ | Tier 3

Invest $2,500 and receive 7% bonus shares.

$5,000+ | Tier 4

Invest $5,000 and receive 10% bonus shares.

$10,000+ | Tier 5

Invest $10,000 and receive 15% bonus shares.

*All perks occur when the offering is completed.

Irregular Use of Proceeds

Example - The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments.


Article Image
'Amytrapper', a Novel Immobilized Sepharose API Matrix, Removes Amyloid-β from Circulation in vitro

Recombinant Technologies LLC (RTL) has developed and studied its proprietary Amytrap peptide to remove Aβ from circulation which in turn depletes brain Aβ in a clinically relevant mouse model of AD. The results provide a proof of concept for our proposed prototype design for an Amytrapper device.

Article Image
Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimer's Disease

Efficacy evaluations were performed on model mice. Pharmacokinetics and safety toxicology were assessed. Post treatment, mice showed significant improvements in cognition. Efficacy and safety features make Amytrap a promising candidate for treating or modulating AD.



Last Chance to invest in this game-changing Alzheimer's Therapeutic/Device

Take Advantage of this last day opportunity before the campaign closes. As for updates we have the following in the pipeline:

1. Two NIH grant proposals are under review

2. Two investment firms and a private high net worth investor are in the process of doing due diligence to get involved with our patented molecule based technologies to treat Alzheimer's Disease. 

3. The valuation potentially could increase many fold if the FDA approves the device within 2-3 years. 

We want the SE community to get the best of this campaign opportunity. So get excited and get involved by investing at the following link

The information included above is forward-looking information. Please refer to our risk factors section in our Form C and to our Forward-Looking Information Legend included in our Terms section on this page.


Final few days to close out this campaign

Only Three Days Left before the campaign closes

You have a very short period of time before the current campaign closes on the SE platform. Get in early and participate in the growth and history of a great disease modifying therapy to treat Alzheimer's and other amyloidosis. Let us join together to make their (AD patients) living better !!!

Here's the link to invest !


Exciting Development

Great News ! We are proud to announce that there are some private clients interested to invest about $ 5 million in our company. This goes to show the confidence from these clients on our technology. We are hoping to finalize the transaction by signing a definitive agreement. This may occur after this offering closes. Once this happens, we will keep the investors and potential investors from start engine posted with details. In addition, I would like to take take this opportunity to thank the current investors for your confidence in our company.  I also encourage all of  you to take advantage  and invest to increase your value along with the company's. You have a very short period of time before the current campaign closes on the SE platform. Here's the link to invest !

The information included above is forward-looking information. Please refer to our risk factors section in our Form C and to our Forward-Looking Information Legend included in our Terms section on this page.


Campaign updated to allow more investors

We are happy to share the exciting news! To those who were worried about missing the boat. In order to accommodate more investors,  Start Engine has extended this campaign by one month. So, get in and be part of the history ! join us in this exciting journey to invest and to help find a possible cure for Alzheimer's Disease !!  Use the link below.

Besides this campaign Recombinant is working to raise private capital via other partners and through grant applications worth about $ 1.8M are under review at the National Institute on Aging,  National institutes of Health. 


Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Recombinant Technologies offering. Here's an excerpt describing the specifics of the change:

Campaign is extending by 30 days.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.


Limited time before the campaign closes

Only a few weeks to get involved before this campaign ends ! Participate in this exciting opportunity to help those affected by Alzheimer's disease. Take a look at this video illustration:


Update from Founder-President

We are thankful for your support. As we enter the new year we have reached a major milestone of $ 75,000 in our campaign raise. With respect to our research front, we are initiating a key animal model testing study in January 2022. Additional research funding (in multimillion dollar grant applications that are in review) is also sought from the National Institute on Aging, NIH. We anticipate positive results in 2022. With your continued help, we hope to able to kickstart the FDA application/approval process for our device, in 2022. Please join us and invest to participate in this exciting journey.

Have a safe and happy new year. 


Brand new Scientific Publication

We're excited to get this publication  out there and hope you'll join us on this journey. Invest today! Invest now and participate in our success. 


Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].


As you might know, Recombinant Technologies has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Recombinant Technologies be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.



Press Releases for Recombinant Technologies

Recombinant has been talked about in various press releases (yahoo finance, marketwatch, Benzinga and seeking alpha).

We have press coverage from various publications this week! 

"Their patented technology was developed over ten years and has successfully improved memory in mice and proof of concept trials."

"Going beyond conventional modalities that only address the symptoms, Recombinant Technologies is focused on treating the root cause of Alzheimer's Disease delivering a huge improvement in the quality of life of those afflicted."

We're excited to get this technology out there and hope you'll join us on this journey. Invest today!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Recombinant Technologies.


StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.


Tier 1

Invest $500 and receive 2% bonus shares.


Tier 2

Invest $1,000 and receive 5% bonus shares.


Tier 3

Invest $2,500 and receive 7% bonus shares.


Tier 4

Invest $5,000 and receive 10% bonus shares.


Tier 5

Invest $10,000 and receive 15% bonus shares.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.